Article Text

Download PDFPDF

Journal club
Ambrisentan for pulmonary fibrosis
  1. Ravi Punwani
  1. Correspondence to Dr Ravi Punwani, The Royal Marsden NHS Foundation Trust, Down's Road, Sutton, Surrey SM2 5PT, UK; ravi.punwani{at}

Statistics from

This randomised, double-blind, placebo-controlled study is one of the largest multicentre studies investigating whether ambrisentan (an endothelin A receptor antagonist) reduces the rate of idiopathic pulmonary fibrosis (IPF) progression.

The investigators compared ambrisentan (more commonly used in the treatment of pulmonary hypertension (PH)) with placebo on the basis of preclinical studies suggesting endothelin …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.